Cardiovascular risk during therapy with Etoricoxib in rheumatology — an unanswered question
I.Z. Gaydukova1,2, V.I. Mazurov1,2, O.V. Inamova1,2, E.A. Vasilenko1,2
1North-western State Medical University named after I.I. Mechnikov, Saint Petersburg
2Clinical Rheumatology Hospital, Saint Petersburg
The literature review presents current data on the risk of cardiovascular events associated with Etoricoxib intake in patients with rheumatoid arthritis, spondylitis and osteoarthritis. The authors conducted a literary search in the following open medical citation databases: PUBMED, MEDLINE, E-library. The following words were used during the search: “cardiovascular risk”, “coxibs”, “etoricoxib”, “rheumatoid arthritis”, “osteoarthritis”, “ankylosing spondylitis” — in Russian and English for the period until September 1, 2019. The authors analyzed 16 articles, including 3 meta-analyzes and 1 national registry. Given the meta-analyzes results, Etoricoxib does not increase the risk of individual atherothrombotic events. It is possible that Etoricoxib negatively affects cardiovascu lar mortality, increasing it’s rate mainly in people with tumours or diseases of the central nervous system. The article discusses the existing contradictions in the presented literature data. Low doses of Etoricoxib demonstrate greater cardiovascular safety compared with high doses, which suggests the de-escalation regimen substantiation. It should be taken into account that rheumatic diseases without treatment are associated with cardiovascular risk increase, so, a decrease in the disease activity can lead to its reduction.
Keywords: nonsteroidal anti-inflammatory drugs; cyclooxygenase 2; coxibs; Etoricoxib; cardiovascular risk; hypertension; coronary heart disease.
For citation: Gaydukova I.Z., Mazurov V.I., Inamova O.V., Vasilenko E.A. Cardiovascular risk during therapy with Etoricoxib in rheumatology — an unanswered question. RMJ. Medical Review. 2019;11(II):71–74.
2. Каратеев А.Е., Новикова Д.С., Насонов Е.Л. Новые данные, касающиеся безопасности нестероидных противовоспалительных препаратов: представление о «класс-специфическом» высоком кардиоваскулярном риске селективных ингибиторов циклооксигеназы-2 устарело. Научно-практическая ревматология. 2017;55(2):218–223. DOI: 10.14412/1995-4484-2017-218-223. [Karateev A.E., Novikova D.S., Nasonov E.L. New data on the safety of non-steroidal anti-inflammatory drugs: the notion of a “class-specific” high cardiovascular risk of selective cyclooxygenase-2 inhibitors is outdated. Scientific and practical rheumatology. 2017; 55 (2): 218-223. DOI: 10.14412 / 1995-4484-2017-218-223 (in Russ.)].
3. Гайдукова И.З., Ребров А.П., Нам И.Ф., Кирсанова Н.В. Эторикоксиб в лечении активного сакроилеита у больных аксиальными спондилоартритами, включая анкилозирующий спондилит. Терапевтический архив. 2014;86(12):42–47. DOI: 10.17116/terarkh2014861242-47. [Gaydukova I.Z., Rebrov A.P., Nam I.F., Kirsanova N.V. Etoricoxib in the treatment of active sacroiliitis in patients with axial spondyloarthritis, including ankylosing spondylitis. Ther arch. 2014;86(12):42-47. DOI: 10.17116/terarkh2014861242-47 (in Russ.)].
4. Bresalier R.S., Sandler R.S., Quan H. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–1102.
5. Solomon S.D., McMurray J.J., Pfeffer M.A. et al. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 Mar. 17;352(11):1071–1080.
6. De Vecchis R., Baldi C., Di Biase G. et al. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen. Minerva Cardioangiol. 2014;62(6):437–448. Epub 2014 Jul 16.
7. Cannon C.P., Curtis S.P., FitzGerald G.A. et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368(9549):1771–1781.
8. Trelle S., Reichenbach S., Wandel S. et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011 Jan. 11;342:c7086. DOI: 10.1136/bmj.c7086.
9. Hung Y.M., Lin L., Wang Y.H. et al. Combination effect of anti-rheumatic medications for coronary artery diseases risk in rheumatoid arthritis: a nationwide population-based cohort study. Curr Med Res Opin. 2019;35(2):313–320. DOI: 10.1080/03007995.2018.1492910. Epub 2018 Jul 25.
10. Kitas G.D., Gabriel S.E. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis. 2011;70:8–14. DOI: 10.1136/ard.2010.142133.
11. Bremander A., Petersson I.F., Bergman S., Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res. 2011;63:550–556. DOI: 10.1002/acr.20408.
12. Szabo S.M., Levy A.R., Rao S.R. et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum. 2011;63:3294–3304. DOI 10.1002/art.30581.
13. Stevens R.J., Douglas K.M., Saratzis A.N., Kitas G.D. Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med. 2011;7:1–24.
14. Hung Y.M., Lin L., Chen C.M. et al. The effect of anti-rheumatic medications for coronary artery diseases risk in patients with rheumatoid arthritis might be changed over time: A nationwide population-based cohort study. PLoS One. 2017;12(6):e0179081. DOI: 10.1371/journal.pone.0179081. eCollection 2017.
15. Tsai W.C., Ou T.T., Yen J.H. et al. Long-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study. PLoS One. 2015;13;10(5):e0126347. DOI: 10.1371/journal.pone.0126347.
16. Charlson M.E., Pompei P., Ales K.L., MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
17. Balazcs E., Sieper J., Bickham K. et al. A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis. BMC Musculoskelet Disord. 2016;17(1):426.
18. Van der Heijde D., Baraf H.S., Ramos-Remus C. et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum. 2005;52(4):1205–1215.
19. Sasich L.D., Barasain M.A., Al Kudsi M.A. The cardiovascular risks of etoricoxib (Arcoxia). Ann Saudi Med. 2008 Mar-Apr;28(2):141–142. DOI: 10.5144/0256-4947.2008.141.
20. Hippisley-Cox J., Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;330:1366.
21. Johnsen S.P., Larsson H., Tarone R.E. et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med. 2005;165:978–984.
22. Hennekens C.H., Borzak S. Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease. J Cardiovasc Pharmacol Ther. 2008;13:41–50. DOI 10.1177/1074248407312990.
23. Lader E. Review: NSAIDs increase GI and CV events; coxibs increase mortality. Ann Intern Med. 2013;159. DOI JC12 10.7326/0003–4819–159–12–201312170–02012/.
24. Watson D.J., Rhodes T., Cai B., Guess H.A. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 2002;162:1105–1110.
25. Juni P., Nartey L., Reichenbach S. et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004; 364:2021–2029.
26. Goodson N.J., Brookhart A.M., Symmons D.P. et al. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis. 2009;68:367–372. 10.1136/ard.2007.076760.
27. Lindhardsen J., Gislason G.H., Jacobsen S. et al. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2014;73:1515–1521.
28. Collantes E., Curtis S.P., Lee K.W. et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract. 2002;3:10. DOI: 10.1186/1471-2296-3-10.
29. Bakland G., Gran J.T., Nossent J.C. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011 Nov;70(11):1921–1925. DOI: 10.1136/ard.2011.151191. Epub 2011 Jul 21.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
